COPD-associated pulmonary hypertension: clinical implications and current methods for treatment

References

• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365.
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–743.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
   PubMed Web of Science ®Google Scholar
• Maciewicz RA, Warburton D, Rennard SI. Can increased understanding of the role of lung development and aging drive new advances in chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2009;6:614–617.
   PubMedGoogle Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–D50.
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
   Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest. 2012;142:448–456.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108–113.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–3800.
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–1093.
   PubMed Web of Science ®Google Scholar
• Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest. 2010;137:30S–38S.
   Google Scholar
• Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39:112–118.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55–S66.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):S67–119.
   PubMed Web of Science ®Google Scholar
• Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41:1292–1301.
   PubMed Web of Science ®Google Scholar
• Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137:39S–51S.
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555.
   PubMedGoogle Scholar
• Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(1):55–70.
   PubMedGoogle Scholar
• Chaouat A, Naeije R, Cha E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371–1385.
   PubMed Web of Science ®Google Scholar
• Stevens D, Sharma K, Szidon P, et al. Severe pulmonary hypertension associated with COPD. Ann Transplant. 2000;5:8–12.
   PubMedGoogle Scholar
• Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531–1536.
   PubMed Web of Science ®Google Scholar
• Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31:373–380.
   PubMed Web of Science ®Google Scholar
• Burrows B, Kettel LJ, Niden AH, et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972;286:912–918.
   PubMed Web of Science ®Google Scholar
• Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107:1193–1198.
   PubMed Web of Science ®Google Scholar
• Sims MW, Margolis DJ, Localio AR, et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest. 2009;136:412–419.
   PubMed Web of Science ®Google Scholar
• Wright JL, Lawson L, Pare PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis. 1983;128:702–707.
   PubMed Web of Science ®Google Scholar
• Kubo K, Ge RL, Koizumi T, et al. Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema. Respir Physiol. 2000;120:71–79.
   PubMedGoogle Scholar
• Wrobel JP, Thompson BR, Stuart-Anderws CR, et al. Intermittent positive pressure ventilation increases diastolic pulmonary artery pressure in advanced COPD. Heart Lung. 2015;44:50–56.
   PubMed Web of Science ®Google Scholar
• Falk JA, Martin UJ, Scharf S, et al. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest. 2007;132:1476–1484.
   PubMed Web of Science ®Google Scholar
• Hilde JM, Skjorten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J. 2013;41:1031–1041.
   PubMed Web of Science ®Google Scholar
• Von Euler U. Liljerstrand. Observations on the pulmonary arterial blood pressure in the cat. Adv Pulmon Hypertens. 1946;12:301–320.
   Google Scholar
• Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675–691.
   PubMed Web of Science ®Google Scholar
• Magee F, Wright JL, Wiggs BR, et al. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax. 1988;43:183–189.
   PubMed Web of Science ®Google Scholar
• Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest. 2008;134:808–814.
   PubMed Web of Science ®Google Scholar
• Peinado VI, Barberà JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1605–1611.
   PubMed Web of Science ®Google Scholar
• Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632–638.
   PubMed Web of Science ®Google Scholar
• Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324:1539–1547.
   PubMed Web of Science ®Google Scholar
• Lee JD, Taraseviciene-Stewart L, Keith R, et al. The expression of prostacyclin synthase is decreased in the small pulmonary arteries from patients with emphysema. Chest. 2005;128:575S.
   Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–1739.
   PubMed Web of Science ®Google Scholar
• Spiropoulos K, Trakada G, Nikolaou E, et al. Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respir Med. 2003;97:983–989.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136:678–687.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Chi SY, Shin HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci. 2010;25:1487–1491.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003;108:1839–1844.
   PubMed Web of Science ®Google Scholar
• Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell. 2011;147:293–305.
   PubMed Web of Science ®Google Scholar
• Ferrer E, Peinado VI, Castaneda J, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J. 2011;38:617–627.
   PubMed Web of Science ®Google Scholar
• Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011;183:50–58.
   PubMed Web of Science ®Google Scholar
• Barbera JA, Peinado VI, Santos S, et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med. 2001;164:709–713.
   PubMed Web of Science ®Google Scholar
• Loddenkemper R, Gibson GJ, Sibille Y, et al. European lung white book: the first comprehensive survey on respiratory health in Europe. Sheffield: European Respiratory Society Journals; 2003.
   Google Scholar
• Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:349–355.
   PubMed Web of Science ®Google Scholar
• Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760–765.
   PubMed Web of Science ®Google Scholar
• Barbara J, Roca J, Ferrer A. Mechanisms of worsening gas exchange during acute exacerbation of chronic obstructive pulmonary disease. Eur Resp J. 1997;10:1285–1291.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Raisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir Mon. 1998;7:107–126.
   Google Scholar
• O’Aonell D, Parker C. COPD exacerbations-3: pathophysiology. Thorax. 2006;61:354–361.
   PubMed Web of Science ®Google Scholar
• Scott KW. A clinicopathological study of fatal chronic airways obstruction. Thorax. 1976;31:693–701.
   PubMed Web of Science ®Google Scholar
• Chiang GG, Weinmann YP, Sheingold S. The National Emphysema Treatment Trial (NETT): a study in agency collaboration. Proc Am Thorac Soc. 2008;5:381–384.
   PubMedGoogle Scholar
• MacNee W, Wathen CG, Flenley DC, et al. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis. 1988;137:1289–1295.
   PubMed Web of Science ®Google Scholar
• Weitzenblum E, Apprill M, Oswald M, et al. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest. 1994;105:1377–1382.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: Royal College of Physicians (UK); 2010 Jun. (NICE Clinical Guidelines, No. 101.)
   Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946.
   PubMed Web of Science ®Google Scholar
• Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. Jama. 2013;309:2223–2231.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138–1180.
   PubMed Web of Science ®Google Scholar
• Austin MA, Wills KE, Blizzard L, et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. Bmj. 2010;341:c5462.
   PubMed Web of Science ®Google Scholar
• Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med. 1995;151:1799–1806.
   PubMed Web of Science ®Google Scholar
• Plant P, Owen J, Elliott MW. Early use of noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease on general repiratory wards: a multicentre randomised controlled trial. Lancet. 2000;355:1931–1935.
   PubMed Web of Science ®Google Scholar
• Consensus conference report. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation–a consensus conference report. Chest. 1999;116:521–534.
   PubMed Web of Science ®Google Scholar
• Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis. BMJ. 2003;326:185.
   PubMed Web of Science ®Google Scholar
• Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333:817–822.
   PubMed Web of Science ®Google Scholar
• Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet. 1993;341:1555–1557.
   PubMed Web of Science ®Google Scholar
• Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. Am J Respir Crit Care Med. 2012;185:152–159.
   PubMed Web of Science ®Google Scholar
• Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med. 1994;120:760–770.
   PubMed Web of Science ®Google Scholar
• Kessler R, Faller M, Weitzenblum E, et al. “Natural History” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:219–224.
   PubMed Web of Science ®Google Scholar
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the medical research council working party. Lancet. 1981;1:681–686.
   PubMedGoogle Scholar
• Vonk Noordegraaf A, Marcus JT, Holverda S, et al. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest. 2005;127:1898–1903.
   PubMed Web of Science ®Google Scholar
• MacNee W. Right heart function in COPD. Semin Respir Crit Care Med. 2010;31:295–312.
   PubMed Web of Science ®Google Scholar
• Vonk NA, Marcus JT, Roseboom B, et al. The effect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary emphysema. Chest. 1997;112:640–645.
   PubMed Web of Science ®Google Scholar
• Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135:786–793.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189–194.
   PubMed Web of Science ®Google Scholar
• Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735–740.
   PubMed Web of Science ®Google Scholar
• Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J. 2007;30:914–921.
   PubMed Web of Science ®Google Scholar
• Howard LS, Grapsa J, Dawson D, et al. Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev. 2012;21:239–248.
   PubMedGoogle Scholar
• Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173:744–750.
   PubMed Web of Science ®Google Scholar
• Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest. 2012;142:1166–1174.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu K, Wang Z, et al. Computed tomography measurement of pulmonary artery for diagnosis of COPD and its comorbiditiy pulmonary hyerptension. Int J Chron Obstruct Pulmon Dis. 2015;10:2525–2533.
   PubMed Web of Science ®Google Scholar
• Dournes G, Laurent F, Coste F, et al. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. Am J Respir Crit Care Med. 2015;191:63–70.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Washko GR, Yamashiro T, et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med. 2010;181:218–225.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43–S54.
   PubMed Web of Science ®Google Scholar
• Chabot F, Schrijen F, Poincelot F, et al. Interpretation of high wedge pressure on exercise in patients with chronic obstructive pulmonary disease. Cardiology. 2001;95:139–145.
   PubMed Web of Science ®Google Scholar
• Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:506–512.
   PubMedGoogle Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391–398.
   PubMed Web of Science ®Google Scholar
• Pizarro C, Schueler R, Hammerstingl C, et al. Impact of endoscopic lung volume reduction on right ventricular myocardial function. PLoS One. 2015;10:e0121377.
   Google Scholar
• Eberhardt R, Gerovasili V, Kontogianni K, et al. Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension. Respiration. 2015;89:41–48.
   PubMed Web of Science ®Google Scholar
• Barbera JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs. 2009;69:1153–1171.
   PubMed Web of Science ®Google Scholar
• Valerio G, Bracciale P, Grazia DA. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3:15–21.
   PubMedGoogle Scholar
• Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32:619–628.
   PubMed Web of Science ®Google Scholar
• Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181:270–278.
   PubMed Web of Science ®Google Scholar
• Alp S, Skrygan M, Schmidt WE, et al. Sildenafil improves hemodynamic parameters in COPD - an investigation of six patients. Pulm Pharmacol Ther. 2006;19:386–390.
   PubMed Web of Science ®Google Scholar
• Rao RS, Singh S, Sharma BB, et al. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci. 2011;53:81–85.
   PubMedGoogle Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Brundage BH, Galiè N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60:768–774.
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2:293–300.
   PubMed Web of Science ®Google Scholar
• Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration. 2010;79:377–382.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Staehler G, Grunig E, et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ. 2015;5:296–304.
   PubMed Web of Science ®Google Scholar
• Girard A, Jouneau S, Chabanne C, et al. Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. Respiration. 2015;90:220–228.
   PubMed Web of Science ®Google Scholar
• Brewis MJ, Church AC, Johnson MK, et al. Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. Eur Respir J. 2015;46(5):1378–1389.
   PubMed Web of Science ®Google Scholar
• Seimetz M, Parajuli N, Pichl A, et al. Cigarette smoke-induced emphysema and pulmonary hypertension can be prevented by phosphodiesterase 4 and 5 inhibition in mice. PLoS One. 2015;10:e0129327.
   PubMed Web of Science ®Google Scholar
• Weissmann N, Lobo B, Pichl A, et al. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med. 2014;189:1359–1373.
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62:D100–D108.
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med. 2007;176:1138–1145.
   PubMed Web of Science ®Google Scholar